Looks like Edison’s phase 2 study was delayed due to Covid. Results aren’t due until end of 1st quarter 2021, so BOT is slightly in front. I would suggest, IMO, they are a much greater long shot than BOT. BOT is dealing with a compound that already has a known safety profile and the support of multiple university studies. Proof will be in the pudding, a snotty one.
Looks like Edison’s phase 2 study was delayed due to Covid....
-
- There are more pages in this discussion • 7,621 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.010(2.90%) |
Mkt cap ! $597.3M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.8¢ | $1.697M | 5.096M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 187040 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 206069 | 6 |
View Market Depth
| Last trade - 15.30pm 05/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |